At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 68 enrolled
Drug / intervention
NB medication (Naltrexone Bupropion combination) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity
In Brief
A Phase 3 clinical trial evaluating NB medication (Naltrexone Bupropion combination) and Placebo for Binge-Eating Disorder and Obesity. Completed, enrolled 68 participants across 1 site.
Detailed Summary
This study will test the effectiveness and relative efficacy of naltrexone/bupropion medication as a maintenance therapy for the treatment of binge eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst responders to acute treatments, naltrexone/bupropion medication results in superior maintenance and longer-term outcomes compared with placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBinge-Eating Disorder, Obesity
CountriesUnited States
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartAug 2017
Primary CompletionDec 2021
Study CompletionDec 2022
TodayJul 2026
First PostedFeb 8, 2017
Enrollment StartAug 28, 2017
Primary CompletionDec 16, 2021
Study CompletionDec 16, 2022
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 9.4 years ago
Interventions
NB medication (Naltrexone Bupropion combination)drug
NB medication
Placeboother
Placebo